Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
Pier Paolo M Berton GiachettiCurigliano GiuseppePublished in: Nature reviews. Clinical oncology (2023)